Iovance Biotherapeutics financials
$14.45+31.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99.3M | $71.4M | $86.8M | $67.5M | $60.0M | $49.3M | $73.7M | $58.6M | $31.1M | $715.0K | $482.0K | $469.0K |
| Gross profit | $55.7M | $28.9M | $43.7M | $29.0M | $11.1M | $6.6M | $35.9M | $27.0M | -$262.0K | -$6.5M | -$3.9M | -$3.9M |
| Gross margin | 56.1% | 40.5% | 50.3% | 43.0% | 18.5% | 13.4% | 48.7% | 46.2% | −0.8% | −915.5% | −805.6% | −825.4% |
| Operating income | -$51.9M | -$81.0M | -$73.5M | -$94.9M | -$113.8M | -$121.2M | -$86.6M | -$89.1M | -$101.9M | -$117.7M | -$121.3M | -$118.4M |
| Net income | -$47.3M | -$79.0M | -$71.9M | -$91.3M | -$111.7M | -$116.2M | -$78.6M | -$83.5M | -$97.1M | -$113.0M | -$116.4M | -$113.8M |
| Net margin | −47.6% | −110.7% | −82.9% | −135.3% | −186.2% | −235.5% | −106.6% | −142.7% | −312.2% | −15800.8% | −24145.0% | −24255.9% |
| Diluted EPS | $-0.11 | $-0.19 | $-0.18 | $-0.25 | $-0.33 | $-0.36 | $-0.26 | $-0.28 | $-0.34 | $-0.42 | $-0.45 | $-0.46 |
| EBITDA | -$42.4M | -$72.5M | -$63.5M | -$81.0M | -$104.4M | -$113.2M | -$72.6M | -$81.5M | -$93.4M | -$110.1M | -$114.4M | -$111.4M |
| Operating cash flow | -$60.8M | -$72.1M | -$52.6M | -$78.7M | -$67.4M | -$103.7M | -$73.3M | -$59.0M | -$98.4M | -$122.3M | -$84.0M | -$84.1M |
| Free cash flow | -$66.3M | -$78.7M | -$61.9M | -$89.5M | -$74.9M | -$109.9M | -$77.5M | -$61.3M | -$98.9M | -$126.5M | -$87.5M | -$87.7M |
| Diluted shares | 450.2M | 418.5M | 408.0M | 364.0M | 334.5M | 322.9M | 305.2M | 303.3M | 284.8M | 266.2M | 256.5M | 245.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.8M | $196.5M | $163.1M | $158.1M | $132.5M | $171.7M |
| Short-term investments | $186.9M | $116.9M | $133.9M | $142.7M | $168.7M | $188.0M |
| Total debt | $0.00 | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| Total assets | $915.5M | $925.7M | $913.2M | $904.9M | $907.4M | $966.7M |
| Total liabilities | $179.5M | $203.9M | $214.6M | $202.7M | $208.9M | $198.9M |
| Shareholders' equity | $736.0M | $721.8M | $698.6M | $702.3M | $698.5M | $767.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology